Suzhou Venture Capital Group has invested over 100 million RMB in Meichuang Medical Technology to support the development of domestic biomedical solutions aimed at breaking foreign monopolies on critical medical devices.

Information on the Target

Meichuang Medical Technology Co., Ltd., founded in 2021 and located in the Suzhou High-tech Zone, has been making significant strides in the biomedical field. With a dedicated administrative and production facility spanning 5,400 square meters, the company is recognized as a leading platform for the research, development, manufacturing, and commercialization of high-end implantable and interventional medical devices, primarily utilizing medical-grade expanded polytetrafluoroethylene (ePTFE) materials. The team at Meichuang Medical brings over 30 years of expertise in the peripheral vascular and oncology interventional sectors, successfully attracting many globally renowned scientists and seasoned engineers from both China and the US to build an international team.

The Chinese market for ePTFE-coated stents and artificial blood vessels is currently dominated by foreign giants, and these products have not yet entered the centralized procurement system, resulting in high treatment costs for patients. The emergence of Meichuang Medical offers hope for breaking this monopoly and providing patients with more affordable options. In just a year and a half, the company achieved a technological breakthrough in the production of ePTFE materials, having recently completed the documentation registration for medical devices with the National Medical Products Administration (NMPA) in December 2024.

Industry Overview in the Target’s Specific Country

The biomedical industry in China is rapidly evolving, with increasing investments aimed at developing domestic capacities to reduce reliance on foreign technologies. The government has been implementing policies to promote innovation and domestic